Core Insights - Revvity, Inc. (RVTY) has a market capitalization of $11.4 billion and operates in the global health sciences sector, providing advanced instruments, reagents, software, and services for diagnostics, genomics, drug discovery, and life sciences research [1] Stock Performance - Over the past 52 weeks, RVTY shares have declined by 12.5%, underperforming the S&P 500 Index, which has gained nearly 13%. However, on a year-to-date basis, RVTY shares have increased by 3.7%, outperforming the S&P 500's marginal return [2] - RVTY shares have also lagged behind the State Street Health Care Select Sector SPDR ETF (XLV), which has seen a 6.5% increase over the same period [3] Financial Performance - Revvity reported Q4 2025 results with revenue of $772 million and adjusted EPS of $1.70, driven by strong growth in Diagnostics, which saw fourth-quarter revenue of $390 million, reflecting a 10% reported growth and 7% organic growth. The company has provided optimistic guidance for full-year 2026, forecasting revenue between $2.96 billion and $2.99 billion, with 2% to 3% organic growth and adjusted EPS of $5.35 to $5.45 [6] - For the fiscal year ending December 2026, analysts expect RVTY's adjusted EPS to grow by 6.9% year-over-year to $5.41. The company has a strong earnings surprise history, having exceeded consensus estimates in the last four quarters [7] Analyst Ratings - Among 18 analysts covering RVTY, the consensus rating is a "Moderate Buy," consisting of eight "Strong Buy" ratings, one "Moderate Buy," and nine "Holds" [7] - Baird analyst Catherine Ramsey Schulte raised the price target on Revvity to $129 while maintaining an "Outperform" rating. The mean price target of $119.40 indicates a 19% premium to RVTY's current price levels, while the highest price target of $140 suggests a potential upside of 39.5% [8]